Miquel Bonachera, co-founder and executive director of AB-Biotics, detailed how clinical research on biotics and their health impacts has evolved, from proving probiotics’ safety to developing more targeted solutions in recent years. AB-Biotics has taken a “bottom-up” approach since its conception — identifying a strain based on its mechanism of action and then clinically demonstrating the strain’s health effect. The company has also developed products for oral and cardiovascular health.
Subscribe to our newsletters
By continuing to browse our site you agree to our Privacy Statement















